In a report released on January 5, Mark Massaro from BTIG maintained a Buy rating on Adaptive Biotechnologies (ADPT – Research Report), with a price target of $7.00. The company’s shares closed last Friday at $4.58.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Cerus, and Exact Sciences. According to TipRanks, Massaro has an average return of -16.0% and a 30.80% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Adaptive Biotechnologies with a $8.80 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.79 and a one-year low of $2.61. Currently, Adaptive Biotechnologies has an average volume of 1.52M.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADPT in relation to earlier this year. Last month, Peter Neupert, a Director at ADPT bought 100,000.00 shares for a total of $84,000.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptive Biotechnologies (ADPT) Company Description:
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Read More on ADPT:
- Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
- Adaptive, collaborators to present over 30 abstracts on clonoSEQ MRD testing
- Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
- Biotech Alert: Searches spiking for these stocks today
